Radiopharmaceutical Theranostics Market (Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and Others; Application: Oncology, Cardiology, and Others; Source: Nuclear Reactors and Cyclotrons; End User: Hospitals, Academic & Research Institutes, and Others; and Approach: Targeted Therapeutic [Rx] and Companion Diagnostic [DX])- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2021-2027

The global Radiopharmaceutical Theranostics market gathered revenue around USD 1.0 Billion in 2020 and market is set to grow USD 3.0 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 10% during the prediction period 2021 to 2027.

Radiopharmaceutical Theranostics Market Size 2020 to 2027

Nuclear medicine imaging is primarily based on the principle of using radioactive isotopes attached to specific molecules (i.e., radiopharmaceutical agents or radiotracers) to examine key biologic processes, including disease pathophysiology. Radiopharmaceuticals are agents used for both diagnostic and therapeutic purposes. Organizations across the world classify these differently. According to the WHO, these are categorized into ready-for-use radioactive goods, radionuclide generators, non-radioactive components (“kits”) for the production of labelled compounds containing a radioactive component, and precursors used for radiolabelling other substances prior to administration.

The radiopharmaceutical market is projected to be driven by factors such as increase in therapeutic applications, public awareness, usage of hybrid imaging, technological advancements, efficient diagnosis & treatments, emergence of new radioisotopes, and replacement of traditional equipment.

This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Radiopharmaceutical Theranostics market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Radiopharmaceutical Theranostics market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.

COVID-19 Impact Assessment on Market Landscape

The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.

Radiopharmaceutical Theranostics market report empower readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.

North America to Lead Radiopharmaceutical Theranostics Market

The global radiopharmaceutical theranostics market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2020, followed by Europe. North America accounted for a major share of the global radiopharmaceutical theranostics market in 2020. The high prevalence of neuroendocrine tumors (NETs) drives the radiopharmaceutical theranostics market in North America. Over 12,000 people in the U.S. are diagnosed with neuroendocrine tumors each year. The sensitivity and specificity of Ga-68 and Lu-177 as a theranostics pair have been evaluated in a number of clinical trials. This factor is expected to fuel the growth of the market in the region.

Report Highlights Details
Market Size US$  3.0 Billion by 2027
Growth Rate CAGR of  10% From 2021 to 2027
Base Year 2020
Historic Data 2017 to 2020
Forecast Period 2021 to 2027
Segments Covered  Radioisotope, Application, Source ,End User,Approach, Region
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)
Companies Mentioned Nihon Medi-Physics, ITM Isotopen Technologien München AG, Advanced Accelerator Applications, Telix Pharmaceuticals, GE Healthcare, Theragnostics Ltd, NuView Life Sciences, Jubilant Pharma Limited, Lantheus Holdings, Inc., Curium Pharma, Bayer AG, and Clarity Pharmaceuticals

Competitive Rivalry

Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

  • Company Overview
  • Company Market Share/Positioning Analysis
  • Product Offerings
  • Financial Performance
  • Recent Initiatives
  • Key Strategies Adopted by Players
  • Vendor Landscape
  • List of Suppliers
  • List of Buyers

Some of the prominent players in the Radiopharmaceutical Theranostics Market include:  Nihon Medi-Physics, ITM Isotopen Technologien München AG, Advanced Accelerator Applications, Telix Pharmaceuticals, GE Healthcare, Theragnostics Ltd, NuView Life Sciences, Jubilant Pharma Limited, Lantheus Holdings, Inc., Curium Pharma, Bayer AG, and Clarity Pharmaceuticals.

Unravelling the Critical Segments

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:

Global Radiopharmaceutical Theranostics Market: Segmentation

  • Radiopharmaceutical Theranostics Market, by Radioisotope
    • Technetium-99
    • Gallium-68
    • Iodine-131
    • Iodine-123
    • 18F
    • Y-90
    • Lutetium (Lu) 177
    • Copper (Cu) 67
    • Copper (Cu) 64
    • Others
  • Radiopharmaceutical Theranostics Market, by Application
    • Oncology
    • Cardiology
    • Others
  • Radiopharmaceutical Theranostics Market, by Source
    • Nuclear Reactors
    • Cyclotrons
  • Radiopharmaceutical Theranostics Market, by End User
    • Hospitals
    • Academic & Research Institutes
    • Others
  • Radiopharmaceutical Theranostics Market, by Approach
    • Targeted Therapeutic (Rx)
    • Companion Diagnostic (DX)

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Highlights of the Report:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the market.
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
  • Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the market

Research Methodology

In the study, a unique research methodology is utilized to conduct extensive research on the growth of the Radiopharmaceutical Theranostics market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the Radiopharmaceutical Theranostics market study are as follows - statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the market, and makes the projections on the growth prospects of the Radiopharmaceutical Theranostics markets more accurate and reliable.

Secondary Research

It involves company databases such as Hoover's: This assists us recognize financial information, structure of the market participants and industry competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire based research etc.
  • In order to validate our research findings and analysis we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

Industry participants involved in this research study include:

  • CEOs, VPs, market intelligence managers
  • Procuring and national sales managers technical personnel, distributors and resellers
  • Research analysts and key opinion leaders from various domains

Key Points Covered in Radiopharmaceutical Theranostics market Study:

  • Growth of Radiopharmaceutical Theranostics in 2021
  • Market Estimates and Forecasts (2017-2027)
  •  Brand Share and Market Share Analysis
  •  Key Drivers and Restraints Shaping Market Growth
  •  Segment-wise, Country-wise, and Region-wise Analysis
  •  Competition Mapping and Benchmarking
  •   Recommendation on Key Winning Strategies
  •   COVID-19 Impact on Demand for Radiopharmaceutical Theranostics and How to Navigate
  •   Key Product Innovations and Regulatory Climate
  •   Radiopharmaceutical Theranostics Consumption Analysis
  • Radiopharmaceutical Theranostics Production Analysis
  •  Radiopharmaceutical Theranostics and Management

Chapter 1.    Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.    Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.    Executive Summary

3.1.  Market Snapshot

Chapter 4.    Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.     Raw Material Procurement Analysis

4.3.2.     Sales and Distribution Channel Analysis

4.3.3.     Downstream Buyer Analysis

Chapter 5.    Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.     Market Drivers

5.1.2.     Market Restraints

5.1.3.     Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.     Bargaining power of suppliers

5.2.2.     Bargaining power of buyers

5.2.3.     Threat of substitute

5.2.4.     Threat of new entrants

5.2.5.     Degree of competition

Chapter 6.    Competitive Landscape

6.1.1.     Company Market Share/Positioning Analysis

6.1.2.     Key Strategies Adopted by Players

6.1.3.     Vendor Landscape

6.1.3.1.          List of Suppliers

6.1.3.2.          List of Buyers

Chapter 7.    Global Radiopharmaceutical Theranostics Market, By Radioisotope

7.1.  Radiopharmaceutical Theranostics Market, By Radioisotope, 2021-2027

7.1.1.     Technetium-99           

7.1.1.1.          Market Revenue and Forecast (2016-2027)

7.1.2.     Technetium-99

7.1.2.1.          Market Revenue and Forecast (2016-2027)

7.1.3.     Iodine-131

7.1.3.1.          Market Revenue and Forecast (2016-2027)

7.1.4.     18F

7.1.4.1.          Market Revenue and Forecast (2016-2027)

7.1.5.     Y-90

7.1.5.1.          Market Revenue and Forecast (2016-2027)

7.1.6.     Lutetium (Lu) 177

7.1.6.1.          Market Revenue and Forecast (2016-2027)

7.1.7.     Copper (Cu) 67

7.1.7.1.          Market Revenue and Forecast (2016-2027)

7.1.8.     Copper (Cu) 64

7.1.8.1.          Market Revenue and Forecast (2016-2027)

7.1.9.     Others

7.1.9.1.          Market Revenue and Forecast (2016-2027)

7.1.10.  Iodine-131

7.1.10.1.       Market Revenue and Forecast (2016-2027)

7.1.11.  Iodine-131

7.1.11.1.       Market Revenue and Forecast (2016-2027)

Chapter 8.    Global Radiopharmaceutical Theranostics Market, By Application

8.1.  Radiopharmaceutical Theranostics Market, by Application, 2021-2027

8.1.1.     Oncology

8.1.1.1.          Market Revenue and Forecast (2016-2027)

8.1.2.     Cardiology

8.1.2.1.          Market Revenue and Forecast (2016-2027)

8.1.3.     Others

8.1.3.1.          Market Revenue and Forecast (2016-2027)

Chapter 9.    Global Radiopharmaceutical Theranostics Market, By Source

9.1.  Radiopharmaceutical Theranostics Market, by Source, 2021-2027

9.1.1.     Nuclear Reactors

9.1.1.1.          Market Revenue and Forecast (2016-2027)

9.1.2.     Cyclotrons

9.1.2.1.          Market Revenue and Forecast (2016-2027)

Chapter 10.Global Radiopharmaceutical Theranostics Market, By End User

10.1.          Radiopharmaceutical Theranostics Market, by End User, 2021-2027

10.1.1.  Hospitals

10.1.1.1.       Market Revenue and Forecast (2016-2027)

10.1.2.  Academic & Research Institutes

10.1.2.1.       Market Revenue and Forecast (2016-2027)

10.1.3.  Others

10.1.3.1.       Market Revenue and Forecast (2016-2027)

Chapter 11.Global Radiopharmaceutical Theranostics Market, By Approach

11.1.          Radiopharmaceutical Theranostics Market, by Approach, 2021-2027

11.1.1.  Targeted Therapeutic (Rx)

11.1.1.1.       Market Revenue and Forecast (2016-2027)

11.1.2.  Companion Diagnostic (DX)

11.1.2.1.       Market Revenue and Forecast (2016-2027)

Chapter 12.Global Radiopharmaceutical Theranostics Market, Regional Estimates and Trend Forecast

12.1.          North America

12.1.1.  Market Revenue and Forecast, By Radioisotope (2016-2027)

12.1.2.  Market Revenue and Forecast, by Application (2016-2027)

12.1.3.  Market Revenue and Forecast, by Source (2016-2027)

12.1.4.  Market Revenue and Forecast, by End User (2016-2027)

12.1.5.  Market Revenue and Forecast, by Approach (2016-2027)

12.1.6.  U.S.

12.1.6.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.1.6.2.       Market Revenue and Forecast, by Application (2016-2027)

12.1.6.3.       Market Revenue and Forecast, by Source (2016-2027)

12.1.6.4.       Market Revenue and Forecast, by End User (2016-2027)

12.1.6.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.1.7.  Rest of North America

12.1.7.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.1.7.2.       Market Revenue and Forecast, by Application (2016-2027)

12.1.7.3.       Market Revenue and Forecast, by Source (2016-2027)

12.1.7.4.       Market Revenue and Forecast, by End User (2016-2027)

12.1.7.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.2.          Europe

12.2.1.  Market Revenue and Forecast, By Radioisotope (2016-2027)

12.2.2.  Market Revenue and Forecast, by Application (2016-2027)

12.2.3.  Market Revenue and Forecast, by Source (2016-2027)

12.2.4.  Market Revenue and Forecast, by End User (2016-2027)

12.2.5.  Market Revenue and Forecast, by Approach (2016-2027)

12.2.6.  UK

12.2.6.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.2.6.2.       Market Revenue and Forecast, by Application (2016-2027)

12.2.6.3.       Market Revenue and Forecast, by Source (2016-2027)

12.2.6.4.       Market Revenue and Forecast, by End User (2016-2027)

12.2.6.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.2.7.  Germany

12.2.7.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.2.7.2.       Market Revenue and Forecast, by Application (2016-2027)

12.2.7.3.       Market Revenue and Forecast, by Source (2016-2027)

12.2.7.4.       Market Revenue and Forecast, by End User (2016-2027)

12.2.7.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.2.8.  France

12.2.8.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.2.8.2.       Market Revenue and Forecast, by Application (2016-2027)

12.2.8.3.       Market Revenue and Forecast, by Source (2016-2027)

12.2.8.4.       Market Revenue and Forecast, by End User (2016-2027)

12.2.8.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.2.9.  Rest of Europe

12.2.9.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.2.9.2.       Market Revenue and Forecast, by Application (2016-2027)

12.2.9.3.       Market Revenue and Forecast, by Source (2016-2027)

12.2.9.4.       Market Revenue and Forecast, by End User (2016-2027)

12.2.9.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.3.          APAC

12.3.1.  Market Revenue and Forecast, By Radioisotope (2016-2027)

12.3.2.  Market Revenue and Forecast, by Application (2016-2027)

12.3.3.  Market Revenue and Forecast, by Source (2016-2027)

12.3.4.  Market Revenue and Forecast, by End User (2016-2027)

12.3.5.  Market Revenue and Forecast, by Approach (2016-2027)

12.3.6.  India

12.3.6.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.3.6.2.       Market Revenue and Forecast, by Application (2016-2027)

12.3.6.3.       Market Revenue and Forecast, by Source (2016-2027)

12.3.6.4.       Market Revenue and Forecast, by End User (2016-2027)

12.3.6.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.3.7.  China

12.3.7.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.3.7.2.       Market Revenue and Forecast, by Application (2016-2027)

12.3.7.3.       Market Revenue and Forecast, by Source (2016-2027)

12.3.7.4.       Market Revenue and Forecast, by End User (2016-2027)

12.3.7.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.3.8.  Japan

12.3.8.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.3.8.2.       Market Revenue and Forecast, by Application (2016-2027)

12.3.8.3.       Market Revenue and Forecast, by Source (2016-2027)

12.3.8.4.       Market Revenue and Forecast, by End User (2016-2027)

12.3.8.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.3.9.  Rest of APAC

12.3.9.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.3.9.2.       Market Revenue and Forecast, by Application (2016-2027)

12.3.9.3.       Market Revenue and Forecast, by Source (2016-2027)

12.3.9.4.       Market Revenue and Forecast, by End User (2016-2027)

12.3.9.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.4.          MEA

12.4.1.  Market Revenue and Forecast, By Radioisotope (2016-2027)

12.4.2.  Market Revenue and Forecast, by Application (2016-2027)

12.4.3.  Market Revenue and Forecast, by Source (2016-2027)

12.4.4.  Market Revenue and Forecast, by End User (2016-2027)

12.4.5.  Market Revenue and Forecast, by Approach (2016-2027)

12.4.6.  GCC

12.4.6.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.4.6.2.       Market Revenue and Forecast, by Application (2016-2027)

12.4.6.3.       Market Revenue and Forecast, by Source (2016-2027)

12.4.6.4.       Market Revenue and Forecast, by End User (2016-2027)

12.4.6.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.4.7.  North Africa

12.4.7.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.4.7.2.       Market Revenue and Forecast, by Application (2016-2027)

12.4.7.3.       Market Revenue and Forecast, by Source (2016-2027)

12.4.7.4.       Market Revenue and Forecast, by End User (2016-2027)

12.4.7.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.4.8.  South Africa

12.4.8.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.4.8.2.       Market Revenue and Forecast, by Application (2016-2027)

12.4.8.3.       Market Revenue and Forecast, by Source (2016-2027)

12.4.8.4.       Market Revenue and Forecast, by End User (2016-2027)

12.4.8.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.4.9.  Rest of MEA

12.4.9.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.4.9.2.       Market Revenue and Forecast, by Application (2016-2027)

12.4.9.3.       Market Revenue and Forecast, by Source (2016-2027)

12.4.9.4.       Market Revenue and Forecast, by End User (2016-2027)

12.4.9.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.5.          Latin America

12.5.1.  Market Revenue and Forecast, By Radioisotope (2016-2027)

12.5.2.  Market Revenue and Forecast, by Application (2016-2027)

12.5.3.  Market Revenue and Forecast, by Source (2016-2027)

12.5.4.  Market Revenue and Forecast, by End User (2016-2027)

12.5.5.  Market Revenue and Forecast, by Approach (2016-2027)

12.5.6.  Brazil

12.5.6.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.5.6.2.       Market Revenue and Forecast, by Application (2016-2027)

12.5.6.3.       Market Revenue and Forecast, by Source (2016-2027)

12.5.6.4.       Market Revenue and Forecast, by End User (2016-2027)

12.5.6.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.5.7.  Rest of LATAM

12.5.7.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.5.7.2.       Market Revenue and Forecast, by Application (2016-2027)

12.5.7.3.       Market Revenue and Forecast, by Source (2016-2027)

12.5.7.4.       Market Revenue and Forecast, by End User (2016-2027)

12.5.7.5.       Market Revenue and Forecast, by Approach (2016-2027)

Chapter 13.   Company Profiles

13.1.                 Nihon Medi-Physics

13.1.1.  Company Overview

13.1.2.  Product Offerings

13.1.3.  Financial Performance

13.1.4.  Recent Initiatives

13.2.                 ITM Isotopen Technologien München AG

13.2.1.  Company Overview

13.2.2.  Product Offerings

13.2.3.  Financial Performance

13.2.4.  Recent Initiatives

13.3.                 Advanced Accelerator Applications

13.3.1.  Company Overview

13.3.2.  Product Offerings

13.3.3.  Financial Performance

13.3.4.  Recent Initiatives

13.4.                 Telix Pharmaceuticals

13.4.1.  Company Overview

13.4.2.  Product Offerings

13.4.3.  Financial Performance

13.4.4.  Recent Initiatives

13.5.                 GE Healthcare

13.5.1.  Company Overview

13.5.2.  Product Offerings

13.5.3.  Financial Performance

13.5.4.  Recent Initiatives

13.6.                 Theragnostics Ltd

13.6.1.  Company Overview

13.6.2.  Product Offerings

13.6.3.  Financial Performance

13.6.4.  Recent Initiatives

13.7.                 NuView Life Sciences

13.7.1.  Company Overview

13.7.2.  Product Offerings

13.7.3.  Financial Performance

13.7.4.  Recent Initiatives

13.8.                 Company 8

13.8.1.  Company Overview

13.8.2.  Product Offerings

13.8.3.  Financial Performance

13.8.4.  Recent Initiatives

13.9.                 Jubilant Pharma Limited

13.9.1.  Company Overview

13.9.2.  Product Offerings

13.9.3.  Financial Performance

13.9.4.  Recent Initiatives

13.10.              Lantheus Holdings, Inc.

13.10.1.                   Company Overview

13.10.2.                   Product Offerings

13.10.3.                   Financial Performance

13.10.4.                   Recent Initiatives

Chapter 14.   Research Methodology

14.1.                 Primary Research

14.2.                 Secondary Research

14.3.                 Assumptions

Chapter 15.   Appendix

15.1.                 About Us

15.2.                 Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert